Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Releases Quarterly Earnings Results, Misses Estimates By $2.78 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings results on Wednesday. The company reported ($3.16) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($2.78), FiscalAI reports. The firm had revenue of $0.79 million during the quarter, compared to analysts’ expectations of $0.74 million.

Armata Pharmaceuticals Price Performance

Shares of ARMP traded down $0.18 during trading hours on Wednesday, hitting $8.82. The stock had a trading volume of 27,167 shares, compared to its average volume of 55,359. Armata Pharmaceuticals has a 12 month low of $1.17 and a 12 month high of $16.34. The firm has a market capitalization of $323.61 million, a PE ratio of -1.83 and a beta of 1.31. The stock has a fifty day moving average price of $10.55 and a 200 day moving average price of $8.11.

Institutional Trading of Armata Pharmaceuticals

Large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in shares of Armata Pharmaceuticals by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock worth $690,000 after acquiring an additional 5,342 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Armata Pharmaceuticals by 65.9% in the fourth quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after acquiring an additional 27,200 shares during the period. State Street Corp grew its holdings in shares of Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $284,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Armata Pharmaceuticals in the fourth quarter worth $177,000. Institutional investors own 3.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their price target on Armata Pharmaceuticals from $9.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, Armata Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $15.00.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.